# AbbVie Inc. (ABBV) FY2025 Annual P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2025-01-01 to 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-20, accession number 0001551152-26-000008
- Page: https://plicit.ai/financials/abbv/fy2025-annual-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2025-annual-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2025-01-01 through 2025-12-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 61,160,000,000 US dollars
- **Cost of products sold**: 18,204,000,000 US dollars
- **Gross profit (calculated)**: 42,956,000,000 US dollars
- **Operating expenses (calculated)**: 27,881,000,000 US dollars
- **Operating earnings**: 15,075,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 8,478,000,000 US dollars
- **Earnings before income tax expense**: 6,597,000,000 US dollars
- **Income tax expense (benefit)**: 2,364,000,000 US dollars
- **Net earnings**: 4,233,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 2,602,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 993,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 1,265,000,000 US dollars
- **Eye Care - Alphagan/Combigan**: 197,000,000 US dollars
- **Eye Care - Lumigan/Ganfort**: 410,000,000 US dollars
- **Eye Care - Other Eye Care**: 1,009,000,000 US dollars
- **Eye Care - Ozurdex**: 493,000,000 US dollars
- **Immunology - Humira**: 4,540,000,000 US dollars
- **Immunology - Rinvoq**: 8,304,000,000 US dollars
- **Immunology - Skyrizi**: 17,562,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 3,769,000,000 US dollars
- **Neuroscience - Duodopa**: 381,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 207,000,000 US dollars
- **Neuroscience - Qulipta**: 1,036,000,000 US dollars
- **Neuroscience - Ubrelvy**: 1,271,000,000 US dollars
- **Neuroscience - Vraylar**: 3,621,000,000 US dollars
- **Neuroscience - Vyalev**: 482,000,000 US dollars
- **Oncology - Elahere**: 690,000,000 US dollars
- **Oncology - Epkinly**: 271,000,000 US dollars
- **Oncology - Imbruvica**: 2,869,000,000 US dollars
- **Oncology - Venclexta**: 2,792,000,000 US dollars
- **Other Key Products - Linzess/Constella**: 907,000,000 US dollars
- **Other Key Products - Mavyret**: 1,317,000,000 US dollars
- **Undisclosed (calculated)**: 4,172,000,000 US dollars
- **Selling, general and administrative**: 14,010,000,000 US dollars
- **Research and development**: 9,096,000,000 US dollars
- **Acquired IPR&D and milestones**: 5,016,000,000 US dollars
- **Other operating income**: negative 241,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.23 B; to noncontrolling interests: $7.00 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/abbv/fy2025-annual-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/abbv-fy2025-annual-revenue-by-geography-sankey.png

Income statement for 2025-01-01 through 2025-12-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 61,160,000,000 US dollars
- **Cost of products sold**: 18,204,000,000 US dollars
- **Gross profit (calculated)**: 42,956,000,000 US dollars
- **Operating expenses (calculated)**: 27,881,000,000 US dollars
- **Operating earnings**: 15,075,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 8,478,000,000 US dollars
- **Earnings before income tax expense**: 6,597,000,000 US dollars
- **Income tax expense (benefit)**: 2,364,000,000 US dollars
- **Net earnings**: 4,233,000,000 US dollars
- **UNITED STATES**: 46,603,000,000 US dollars
- **GERMANY**: 1,738,000,000 US dollars
- **JAPAN**: 1,274,000,000 US dollars
- **CANADA**: 1,222,000,000 US dollars
- **CHINA**: 1,006,000,000 US dollars
- **FRANCE**: 806,000,000 US dollars
- **UNITED KINGDOM**: 626,000,000 US dollars
- **SPAIN**: 609,000,000 US dollars
- **ITALY**: 580,000,000 US dollars
- **BRAZIL**: 478,000,000 US dollars
- **AUSTRALIA**: 459,000,000 US dollars
- **All other countries**: 5,759,000,000 US dollars
- **Selling, general and administrative**: 14,010,000,000 US dollars
- **Research and development**: 9,096,000,000 US dollars
- **Acquired IPR&D and milestones**: 5,016,000,000 US dollars
- **Other operating income**: negative 241,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.23 B; to noncontrolling interests: $7.00 M.